SG

Simon Goldman

Partner at AlbionVC

Greater Cambridge Area

Overview

Work Experience

  • Partner

    2016 - Current

    The UCL Technology Fund is dedicated to investing in intellectual property commercialisation opportunities arising from UCL's world-class research base, focusing in particular on the physical and life sciences. The Fund will support academics throughout UCL in achieving the full potential of innovations that have prospects for outstanding societal and market impact, right through the development journey from initial proof of concept to practical application.

  • Fellow Commoner and Director of Studies for Economics

    2007

    Supervising third year undergraduate Banking & Finance students, and Director of Studies for third year undergraduates at Queens' College. Historically teaching first- and second-year macroeconomics, and neuroscience and psychopathology, in highly interactive supervision sessions.

  • Postdoctoral Research Associate

    2012 - 2012

    Design, implementation and analysis of three human trials of a webcam-based platform technology for enabling efficient communication by brain-damaged patients who are unable to read or write (e.g. cerebral palsy, locked-in syndrome).

  • Postdoctoral Research Associate

    2011 - 2012

    Implementation of a large-scale experimental trial to determine if the cues for distinguishing a signal in a noisy background can be immediately utilised by listeners under (often-unnatural) experimental conditions or if they require training in these circumstances. This study was published in the Journal of the Acoustical Society of America, the leading international journal in this field.

  • Doctor of Philosophy

    2006 - 2011

    My PhD examined the cues used by the auditory system to distinguish a signal in a noisy background, differentiating between those cues that are processed at the level of the cochlea and those processed by higher brain centres. All of my research has been published in the Journal of the Acoustical Society of America, the leading international journal in this field.

  • Global Business Development and Project Management

    2013 - 2016

    Abcodia is an innovative company engaged in the discovery and validation of biomarkers for the early detection and screening of disease. Currently engaged in global business development for Abcodia’s biomarker-validation business, across all disease areas and medical/assay technologies. Detailed assessment of biochemical and molecular-biological targets, networking/sourcing leads across biotech/academia/pharma, trial design/analysis, contract negotiation and deal execution, service delivery and relationship management. I also project-managed the launch of a major new ovarian-cancer screening test which is now available in the UK market.

  • Consultant

    2013 - 2013

    I provided key consulting services to the Victorian Biotechnology Advisory Council which "has been established to assist the [Victorian State] Government in providing a far-sighted and coordinated approach to the development of the Victorian biotechnology industry."

  • Tutor

    2013 - 2013

    I teach undergraduate Business Finance when in Australia.

  • Strategy Consultant

    2012 - 2012

    I delivered several strategy-consultancy projects for Evans and Partners, an Australian boutique investment bank. I also wrote a series of research articles on the innovation industry in Australia (and globally) for the firm’s client base, to stimulate interest in the asset class and inform policy in the sector.

  • Assistant Analyst (Portfolio Strategy)

    2003 - 2006

    Portfolio strategy across all asset classes, with a particular focus on using the fundamental work of the Investment Research division through economic and market analysis and quantitative portfolio construction and risk modelling.

  • Professional Development Programme

    2003 - 2003

  • Assistant Analyst (Healthcare & Biotechnology)

    2000 - 2002

    Fundamental, industry and company analysis in the Australian listed Healthcare & Biotechnology sector to develop stock recommendations for Goldman Sachs JBWere's institutional and private wealth clients.

Relevant Websites